Background: Cell Microarray (CMA) technology has been established as an essential tool for advancing cancer studies, allowing for the simultaneous protein analysis of multiple samples [1]. This method facilitates the exploration of various biomarkers associated with diagnosis, prognosis, and therapeutic response, making evaluation processes more efficient and comprehensive [1]. Carboplatin and paclitaxel are co...